Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Class A

Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Class A

SSSE:605016
19.82
CNY
-0.40
(-1.98%)
0.95EPS
22.28P/E
8.87BMarket Cap
Apr 23Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.25
0.99
1.13
1.34
1.59
2.38
1.73
2.08
2.72
3.29
3.68
Basic EPS, GAAP
0.24
0.2
0.21
0.26
0.3
0.38
0.36
0.46
0.58
0.88
0.95
Free Cash Flow per Basic Share
0.12
0.24
- -
0.02
0.2
0.15
-0.06
-0.28
0.05
-0.39
- -
Dividend per Share
0.07
0.03
0.01
0.01
0.01
- -
0.03
0.08
0.18
0.22
0.31
Book Value per Share
1.15
1.39
1.63
1.9
2.2
2.87
3.2
3.59
4
4.67
5.13
Tangible Book Value per Share
1.1
1.33
1.57
1.84
2.15
2.83
3.17
3.56
3.96
4.63
5.08
Basic Weighted Avg Shares
268
315
313
315
313
275
418
418
423
419
419
Sales/Revenue/Turnover
336
311
356
421
500
653
722
868
1,152
1,379
1,543
Operating Margin (%)
25.12
26.15
22.13
23.98
23.76
18.35
21.95
24.17
23.98
32.52
32.41
Depreciation Expense
25
26
28
32
43
47
47
46
77
99
- -
Net Income, GAAP
65
64
65
83
96
104
151
193
246
369
397
Effective Tax Rate (%)
15.28
14.04
13.74
13.85
13.21
12.04
12.91
12.88
13.92
14.74
14.33
Profit Margin (%)
19.31
20.52
18.37
19.66
19.12
15.99
20.88
22.23
21.33
26.72
25.72
Working Capital
62
121
131
135
239
761
734
532
599
771
740
LT Debt
- -
- -
- -
- -
- -
1
- -
1
1
80
301
Total Equity
363
436
513
597
691
1,203
1,345
1,508
1,679
1,961
2,154
Return on Invested Capital (%)
- -
11.36
11.72
13.98
13.69
10.82
12.1
13.7
15.33
18.99
16.23
Return on Capital (%)
- -
12.44
12.11
13.91
14.07
10.72
11.82
13.65
15.49
19.26
16.6
Return on Common Equity (%)
- -
15.95
13.76
14.92
14.84
11.03
11.83
13.53
15.41
20.25
20.06

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
343
318
298
LT Borrowings
120
131
294
LT Finance Leases
3
8
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
420
420
420
Market Capitalization
10,458
10,857
8,866

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,404
1,322
1,316
Cash, Cash Equivalents & STI
702
652
614
Accounts Receivable, Net
344
296
293
Inventories
303
327
360
Total Current Liabilities
560
568
576
Payables & Accruals
- -
- -
- -
ST Debt
343
318
298
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
25.24%
16.81%
Free Cash Flow
- -
-181.29%
-945.38%
Net Income, GAAP
- -
31.79%
50.06%
Sales/Revenue/Turnover
- -
22.79%
19.75%
Total Cash Common Dividend
- -
200.22%
19.02%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
252
279
289
331
1,152
2025
313
336
- -
410
1,379
2026
393
367
374
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.16
0.15
0.15
0.58
2025
0.25
0.21
- -
0.25
0.88
2026
0.29
0.21
0.2
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.14
0.02
0.02
0.18
2025
- -
0.11
- -
0.05
0.22
2026
- -
0.17
0.08
- -
- -

Company Description

CEO
Hong Jian Zhuo
Full Time Employees
990
Sector
Consumer non-durables
Industry
Food: specialty/candy
Address
National High-tech Industrial Development Zone Dezhou China 251200
IPO Date
Apr 21, 2021
Business
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. specializes in the research, development, production, and sale of functional sugars, dietary fibers, prebiotics, and healthy sweeteners. Its product portfolio includes prebiotic fibers such as fructo-oligosaccharide, isomalto-oligosaccharide, galacto-oligosaccharide, and xylo-oligosaccharide; dietary fibers like polydextrose and resistant dextrin; and starch sugars including allulose, maltitol, maltodextrin, allulose psicose, and isomaltulose available in powder and syrup forms. The company's products cater primarily to the food, pharmaceutical, health product, and feed industries. Founded in 2005 and headquartered in Yucheng, Shandong Province, China, it operates globally across Asia, Africa, Europe, Australia, and the Americas. Recent strategic initiatives include expanding its allulose product portfolio with a crystalline form certified as Non-GMO Project Verified to meet growing market demand for healthier sugar alternatives. The company is investing approximately CNY 452 million (USD 61.8 million) in building an artificial sweetener factory in Thailand to reduce trade barriers and production costs, particularly targeting the U.S. market. It also concluded a funding round providing THB 105 million for its subsidiary Bailong Chuangyuan (Thailand) Co., Ltd., supporting regional expansion. New acquisitions of two local biotechnology firms have bolstered its revenue base and enhanced its technological capabilities. The company emphasizes sustainability through investments in green production technologies and maintains certifications including BRCGS, ISO, HALAL, KOSHER, Non-GMO, and Organic. Shandong Bailong Chuangyuan integrates R&D, manufacturing, sales, and service, serving major customers such as Unilever, Mars, and Nestle. The company covers a production area of over 139,000 square meters, with an annual capacity of 300,000 tons and employs around 900 staff. It is recognized as a high-tech enterprise and a flagship entity in China’s functional sugar industry and bioengineering sector, with a strong focus on innovative health ingredient solutions and global market development.